Publicacións nas que colabora con Ángel Cosme Jiménez (65)

2021

  1. Antibiotic resistance prevalence and trends in patients infected with helicobacter pylori in the period 2013–2020: Results of the european registry on h. pylori management (hp-eureg)

    Antibiotics, Vol. 10, Núm. 9

  2. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

  3. Follow-up study confirms the presence of gastric cancer dna methylation hallmarks in high-risk precursor lesions

    Cancers, Vol. 13, Núm. 11

2019

  1. Autoamputation of a polypoid carcinoma of the rectum

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 8, pp. 486-487

  2. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies

    Helicobacter, Vol. 24, Núm. 1

  3. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain

    European Journal of Clinical Investigation, Vol. 49, Núm. 8

  4. Short article: Hormone therapy for severe gastrointestinal bleeding due to multiple angiodysplastic lesions

    European Journal of Gastroenterology and Hepatology, Vol. 31, Núm. 3, pp. 312-315

2018

  1. Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14

    International Journal of Cancer, Vol. 143, Núm. 11, pp. 2777-2786

2017

  1. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance

    World Journal of Gastroenterology, Vol. 23, Núm. 18, pp. 3367-3373

  2. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

  3. Triple synchronous gastric tumors: A rare combination diffuse adenocarcinoma, B-cell MALT lymphoma and large cell neuroendocrine carcinoma

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 10, pp. 675-677

2016

  1. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance

    Helicobacter, Vol. 21, Núm. 1, pp. 29-34

  2. Effect of pravastatin on the survival of patients with advanced gastric cancer

    Oncotarget, Vol. 7, Núm. 4, pp. 4379-4384

  3. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: Results of the Spanish follow-up multicenter study

    Journal of Gastroenterology and Hepatology (Australia), Vol. 31, Núm. 5, pp. 953-958

2015

  1. Colorectal cancer in a second round after a negative faecal immunochemical test

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 7, pp. 813-818

2014

  1. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions

    European Journal of Gastroenterology and Hepatology, Vol. 26, Núm. 12, pp. 1380-1384

  2. Effect of oral anticoagulants on the outcome of faecal immunochemical test

    British Journal of Cancer, Vol. 110, Núm. 5, pp. 1334-1337

  3. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. Alcohol consumption on pancreatic diseases

    World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647

  2. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test

    Mayo Clinic Proceedings